Q1 EPS Estimates for Sanara MedTech Lowered by HC Wainwright

Sanara MedTech Inc. (NASDAQ:SMTI) – Stock analysts at HC Wainwright decreased their Q1 2026 earnings per share estimates for Sanara MedTech in a note issued to investors on Monday, January 26th. HC Wainwright analyst Y. Chen now expects that the company will earn $0.13 per share for the quarter, down from their previous estimate of $0.15. HC Wainwright has a “Buy” rating and a $36.00 price objective on the stock. The consensus estimate for Sanara MedTech’s current full-year earnings is ($1.10) per share. HC Wainwright also issued estimates for Sanara MedTech’s Q2 2026 earnings at $0.15 EPS, Q3 2026 earnings at $0.17 EPS, Q4 2026 earnings at $0.19 EPS and FY2026 earnings at $0.65 EPS.

Sanara MedTech (NASDAQ:SMTI) last released its quarterly earnings results on Wednesday, November 12th. The company reported $0.09 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.33. Sanara MedTech had a negative return on equity of 21.33% and a negative net margin of 36.79%.The business had revenue of $26.33 million during the quarter, compared to the consensus estimate of $26.63 million.

Several other brokerages also recently issued reports on SMTI. Wall Street Zen downgraded shares of Sanara MedTech from a “buy” rating to a “hold” rating in a report on Saturday, November 1st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sanara MedTech in a research note on Thursday, January 22nd. Finally, Zacks Research cut Sanara MedTech from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 20th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $41.00.

Sanara MedTech Price Performance

Shares of NASDAQ SMTI opened at $21.38 on Wednesday. The company has a current ratio of 1.80, a quick ratio of 1.60 and a debt-to-equity ratio of 7.34. The company’s 50-day moving average price is $22.88 and its 200 day moving average price is $27.18. Sanara MedTech has a 52 week low of $18.90 and a 52 week high of $37.91. The stock has a market cap of $190.28 million, a price-to-earnings ratio of -5.07 and a beta of 1.06.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Stonebridge Wealth Management LLC purchased a new stake in shares of Sanara MedTech in the second quarter valued at $3,397,000. Marshall Wace LLP lifted its holdings in shares of Sanara MedTech by 144.3% during the 2nd quarter. Marshall Wace LLP now owns 71,511 shares of the company’s stock worth $2,030,000 after acquiring an additional 42,237 shares during the period. Squarepoint Ops LLC boosted its position in shares of Sanara MedTech by 343.4% in the third quarter. Squarepoint Ops LLC now owns 31,383 shares of the company’s stock worth $996,000 after acquiring an additional 24,305 shares during the last quarter. Hsbc Holdings PLC acquired a new position in Sanara MedTech during the second quarter worth approximately $382,000. Finally, Vanguard Group Inc. raised its stake in Sanara MedTech by 3.4% during the third quarter. Vanguard Group Inc. now owns 182,032 shares of the company’s stock worth $5,776,000 after purchasing an additional 6,049 shares during the period. Hedge funds and other institutional investors own 8.10% of the company’s stock.

About Sanara MedTech

Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company’s core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies.